Mycobacterium tuberculosis isoniazid and fluoroquinolone resistance gene test kit (fluorescence PCR)

Product Information

Product abbreviation: iFIND IFQ

Detection Index: Isoniazid, Fluoroquinolone

Cat. No. : 10T/box – 10210102A; 50T/box – 10210102B

All specifications: 10T/box, 50T/box

Multiplex PCR melting curve technology can be used to simultaneously and rapidly detect the resistance of Mycobacterium tuberculosis to the first-line drug isoniazid (detecting katG and inhA genes) and the important second-line drug fluoroquinolones (detecting gyrA gene), and the whole process from nucleic acid extraction to result interpretation can be completed within 2 hours. The kit has the characteristics of fast detection, high sensitivity and good specificity, which can accurately identify drug-resistant strains in clinical samples, providing an important basis for medication guidance, treatment failure case analysis and treatment plan formulation of MDR-TB patients in drug-resistant tuberculosis patients, and is an ideal detection tool for precise treatment of tuberculosis and drug resistance prevention and control.

Mycobacterium tuberculosis isoniazid and fluoroquinolone resistance gene test kit (fluorescence PCR)

Current Status

The situation of drug-resistant tuberculosis (DR-TB) is becoming increasingly severe. According to WHO 2024 data, the global isoniazid resistance rate is as high as 15.6%, the fluoroquinolone resistance rate reaches 6.8%, and the fluoroquinolone resistance rate among multidrug-resistant tuberculosis (MDR-TB) patients has risen to 22.4%. The proportion of dual resistance to isoniazid and fluoroquinolones has reached 4.3%, and patients with such resistance face a treatment cycle of 18-24 months with a success rate of less than 50%. However, traditional detection methods have obvious shortcomings: culture-based drug susceptibility testing takes 2-8 weeks, delaying treatment opportunities; most molecular detection methods only cover rifampicin resistance and cannot simultaneously detect isoniazid and fluoroquinolone resistance; moreover, traditional methods are complex to operate, with coverage rate less than 30% at the primary care level. Therefore, developing a molecular detection kit that can simultaneously detect isoniazid and fluoroquinolone resistance, complete testing within 2 hours, feature high sensitivity and simple operation has become an urgent need to achieve precise diagnosis and treatment of TB and prevention and control of drug resistance.

iFIND Solution

The iFIND TB Drug Resistance Detection System adopts advanced multiplex PCR melting curve technology, which breakthroughly achieves simultaneous detection of resistance to isoniazid (katG/inhA genes) and fluoroquinolones (gyrA gene). This technology has three core advantages: first, it can simultaneously obtain resistance results for two key drugs in a single test, completely solving the cumbersome process of step-by-step detection required by traditional methods; second, through high-specificity melting curve analysis, it can accurately identify key drug-resistant mutation sites, significantly improving the detection rate of low-abundance variants; most importantly, this technology fills the technical gap in the field of fluoroquinolone resistance detection in China, and its simple operation process perfectly overcomes the pain point of complexity and poor usability of existing detection methods, providing clinicians with an efficient and accurate solution for drug resistance detection.